DiaMedica Therapeutics Inc (NAS:DMAC)

Q3 2025 DiaMedica Therapeutics Inc Earnings Call Transcript

Nov 13, 2025 / 01:00 PM GMT

Release Date Price: $5.42 (-14.10%)

Transcript 10-Q8-K

Key Points

Positve

DiaMedica Therapeutics Inc (DMAC) reported meaningful progress in their clinical programs, particularly with their lead product candidate, DM199, which shows promise in treating preeclampsia and other vascular-related conditions.
Interim results from the phase 2 trial in South Africa demonstrated DM199's potential to control maternal hypertension and improve placental perfusion, indicating its potential as a first-in-class treatment for preeclampsia.
The company has a strong cash position of $55.3 million as of September 30, 2025, which is expected to fund planned clinical studies and operations into the second half of 2027.
DiaMedica has completed a productive pre-IND meeting with the FDA, paving the way for a phase 2 preeclampsia trial in the US, targeting early onset preeclampsia patients.
The independent Data Safety Monitoring Board reported no safety concerns for the stroke trial, allowing enrollment to continue without modification, which is a positive indicator for the ongoing study.

Negative

Enrollment rates for the phase 2B3 stroke trial are lower than initially projected, primarily due to changes in stroke referral patterns and the adoption of new technologies.
The company reported increased net losses of $8.6 million and $24.0 million for the three and nine-month periods ending September 30, 2025, compared to the same periods in 2024.
Research and development expenses have increased significantly due to the progress of clinical trials and global expansion, impacting the company's financials.
General and administrative expenses have risen due to increased non-cash share-based compensation and personnel costs, contributing to the overall increase in net losses.
The company is facing challenges in site activation and enrollment for the stroke trial, with current enrollment rates not meeting initial expectations.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

DMAC.OQ - DiaMedica Therapeutics Inc
Q3 2025 DiaMedica Therapeutics Inc Earnings Call
Nov 13, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, ladies and gentlemen, and welcome to the Diametica Therapeutics Q3 2025 earnings conference call.

An audio recording of this webcast will be available shortly after the call today on Diametica's website at www.Dametica.com in the investor relations section.

After our speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, please press 1 on your telephone keypad.

Before the company proceeds with its remarks, please note that the company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.